Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma

PURPOSE: To evaluate efficacy and safety of anti-PD1 therapy with nivolumab for treatment of advanced hepatocellular carcinoma (HCC). METHODS: From Jan 2016 to Jan 2017, eleven cases of HCC (average age of 51.8-year), 4 at stage B and 7 at stage C, according to Barcelona Clinic Liver Cancer staging,...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Duan, Hui, Xie, Shi-Chun, Lu, Yan-Hua, Bai, Li, Cui, Xiao-Hui, Li, Jie-Yu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722511/
https://www.ncbi.nlm.nih.gov/pubmed/29228559
http://dx.doi.org/10.18632/oncotarget.20029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722511/
https://www.ncbi.nlm.nih.gov/pubmed/29228559
http://dx.doi.org/10.18632/oncotarget.20029

Ejemplares similares